Healthy Volunteers
Conditions
Brief summary
ELA026 is a fully human IgG1 SIRP-directed monoclonal antibody designed to reduce the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Adults.
Detailed description
This is a multi-center, Phase 1, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, PK, and PD of ELA026 following single and multiple IV and/or SC dose administration in healthy adult volunteers, including a subgroup of Japanese volunteers. The study will consist of 2 parts: * Part 1: single ascending doses (SAD) in up to 11 SAD cohorts plus a Japanese cohort * Part 2: multiple doses (MD) up to 6 MD cohorts
Interventions
DRUGELA026
Single dose of ELA026
Sponsors
Electra Therapeutics Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Non-Japanese subjects 19 to 60 years of age. Japanese subjects 20 to 60 years of age. 2. Must be in good general health. 3. No clinically significant abnormal laboratory values during screening. 4. Body mass index of 18 - 32 kg/m2.
Exclusion criteria
1. Clinical diagnosis or laboratory evidence of renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic disease at Screening. 2. Diagnosed with any form of malignancy (except basal cell carcinoma, fully removed). 3. Clinically significant immunodeficiency or autoimmunity assessed by medical history and/or laboratory test results. 4. Active or latent tuberculosis (TB), regardless of treatment history, 5. Positive drug abuse test. 6. Positive HIV, HBV, HCV test results. 7. Clinically significant ECG test results. 8. Clinically significant vital sign results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of Treatment-Emergent Adverse Events [Safety and Tolerability]. | By week 3 |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline of monocytes levels. | By week 3 |
| Change from baseline of lymphocytes levels. | By week 3 |
| Plasma concentrations of ELA026 | By week 3 |
| Comparison of ELA026 Maximum observed drug concentration (Cmax) | By week 3 |
| Comparison of ELA026 Area under the curve plasma concentration versus time curve (AUC) | By week 3 |
| Presence of Anti-drug antibodies to ELA026 | By week 3 |
Countries
Austria, United States
Outcome results
None listed